Discard an Energy from this Pokémon and heal all damage from it.
Your opponent's Active Pokémon is now Poisoned.
Release year for Darkness Ablaze is 2020. Series classification for this set is Sword & Shield.
The checklist contains 201 cards, placing it in a large expansion range. As of 2026, the set is 6 years old and sits in a modern-era collecting window.
Within this set, Toxapex is card number 52 with a Uncommon designation.
Toxapex appears in Darkness Ablaze, released in 2020. The printed flavor text states: "To survive in the cold waters of Galar, this Pokémon forms a dome with its legs, enclosing its body so it can capture its own body heat." Core profile: Its card type is Pokémon.
The rarity label is Uncommon. Printed HP is 130.
Energy typing is Water. Toxapex evolves from Mareanie.
The printed attacks highlight "Recover" and "Poisonous Whip". It is weak to Lightning type energy.
Current market pricing for Toxapex (Darkness Ablaze) sits near $0.17. Week-over-week movement is upward at 6.3%.
It now sits 11.4% above its 30-day average of $0.15. The 90-day window shows a floor near $0.10 and a peak around $0.17 (41% total spread), which maps to moderate-volatility movement.
This version is categorized as Uncommon.
Collectors tracking Toxapex often benchmark it against other Toxapex cards. Comparable entries in this snapshot: 4 cards, 4 distinct sets.
In this sample, pricing ranges between $0.10 and $0.49 (390% total span). Relative to the alternative average ($0.28), this card is -39%.
Notable alternatives include Toxapex #115 (Silver Tempest) at $0.10, Toxapex #69 (Lost Thunder) at $0.49, Toxapex #97 (Unified Minds) at $0.23, and Toxapex #63 (Sun & Moon) at $0.30.
Collector-focused market read: Short-term momentum is positive (6.3% over 7 days), while the card sits 70% above its 90-day low. With a 41% 90-day spread ($0.10-$0.17), this card currently tracks as moderate-volatility.
Versus the 30-day average ($0.15), the card is trading 11.4% higher. Without a consistent graded comp in the current snapshot, live listings are still required for reliable condition-based valuation.
